Analysts’ Top Healthcare Picks: Legend Biotech (LEGN), Biotricity (BTCY)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Legend Biotech (LEGN – Research Report), Biotricity (BTCY – Research Report) and Reviva Pharmaceuticals Holdings (RVPH – Research Report) with bullish sentiments.

Biotricity (BTCY)

In a report released today, Kevin Dede from H.C. Wainwright maintained a Buy rating on Biotricity, with a price target of $4.00. The company’s shares closed last Tuesday at $2.40, close to its 52-week low of $2.14.

According to TipRanks.com, Dede is a 1-star analyst with an average return of -1.5% and a 35.9% success rate. Dede covers the Technology sector, focusing on stocks such as Marathon Digital Holdings, DMG Blockchain Solutions, and AquaBounty Technologies.

Biotricity has an analyst consensus of Moderate Buy, with a price target consensus of $4.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on LEGN:

• LEGN Upcoming Earnings Report: What to Expect?
• AMD upgraded, Electronic Arts downgraded: Wall Street’s top analyst calls
• Legend Biotech initiated with a Buy at Citi
• Legend Biotech price target raised to $85 from $82 at H.C. Wainwright
• Legend Biotech price target raised to $92 from $90 at Barclays